Secondary use of social and health data means that client and register data from social and health care services are used for purposes other than the primary reason for which they were originally collected.
Findata grants permits for the secondary use of social and health data when information is needed from multiple public data controllers, the private sector, Findata’s ready-made datasets, or Kanta services. We compile and preprocess the data while ensuring the protection of citizens’ privacy. In addition, we ensure the anonymity of the published results.
You have rights to your personal data when we process personal data as a data controller.
On this page you’ll find information on the secondary use of social and health data, your data rights, and how to exercise them
What is secondary use of health data?
When you visit a doctor or use social services, information about you is saved in different systems. This information is used to provide you with care and services – this is referred to as primary use.
The data can also be used for other, secondary use purposes. For example, registry studies can use data originating from national or regional health care registers.
Before the data is used for secondary purposes, it is pseudonymised. This means that all directly identifying details (like names or personal ID numbers) are removed or replaced, so individuals cannot be directly identified. For some purposes, such as development and innovation, only anonymous, aggragated statistical data is available.
Using data this way helps improve health and social services for everyone in Finland.
Secondary use purposes:
- Scientific research
- Creating statistics
- Planning and investigation tasks by authorities
- Teaching and education
- Development and innovation
- Knowledge management
- Steering and supervision of social and health care by authorities
Legal framework and your rights
The secondary use of social and health data in Finland is regulated by the Act on the Secondary Use of Social and Health Data (also known as the Secondary Use Act). The act ensures that data is used safely and effectively while protecting individuals’ rights.
Finland uses an opt-out model. This means your data can be used for approved secondary purposes, such as research, without informing you personally each time.
However, under the General Data Protection Regulation (GDPR), you have rights concerning your personal data. These include the right to object if you do not want your data to be used for secondary purposes.
What does Findata do?
Findata is the social and health data permit authority in Finland. Except for our ready-made datasets, we do not permanently store registry data. Instead, we serve as an intermediary between permit applicants (typically researchers) and data controllers, such as wellbeing services counties.
Our responsibilities include:
- Granting permits for the secondary use of social and health data when the requested information is sourced from multiple public data controllers, private service providers, Findata’s ready-made datasets, or the national Kanta services.
- Compiling, preprocessing, and pseudonymising or anonymising the data to ensure it is ready for use while safeguarding individuals’ privacy.
- Maintaining the secure Kapseli® processing environment, where permit holders can access and analyse the data safely.
- Ensuring that published results are anonymised, so no individual can be identified.
Frequently asked questions about the Secondary Use of Social and Health Data
What is a data permit?
A data permit is a fixed-term authorisation granted by a public authority to use individual-level personal data for a specific purpose, for example, for research, compiling statistics or carrying out official duties.
Once a data permit is granted, the dataset is delivered to the processor in a pseudonymised format. This means that identifying information has been replaced with codes, so individuals cannot be directly identified. The data may only be processed in a secure processing environment with no direct internet access.
Data permits are particularly important in registry-based research, where data originally collected in social and healthcare client or patient registers is used for secondary purposes.
Read more:
What is Findata?
Findata is the social and health data permit authority in Finland. It was established in 2019, and its operations are based on the Act on the Secondary Use of Health and Social Data, commonly known as the Secondary Use Act.
We grant data permits for the secondary use of health and social data when the data is needed from multiple public data controllers, from the private sector, from Findata’s ready-made datasets, or from the Kanta Services. We compile and preprocess the datasets with strict attention to protecting individuals’ privacy.
Findata also maintains the secure Kapseli® processing environment, where individual-level data is processed safely.
Can individuals be identified from the data?
When we grant a data permit, we provide pseudonymised individual-level data. This means that, for example, names and personal identity numbers are replaced with codes, so the data cannot be directly linked to individuals. We only release identifiable data for particularly justified and necessary reasons.
Pseudonymised data is still personal data. It may only be processed in a secure environment with no direct internet access. The data permit holder or data processor commits to conditions that prohibit attempts to identify individuals from pseudonymised data.
The data processor must produce published results in an anonymous form, from which individual persons or their characteristics cannot be identified. Findata ensures that the results meet the anonymity requirements set out in the Secondary Use Act.
If the permit concerns statistical-level data (data request), we provide anonymous data that describes population groups rather than individuals. Statistical data cannot be traced back to or used to identify individuals.
Read more:
For what purposes can social and health data be used?
The secondary use of social and health data is only permitted for purposes defined by law, such as:
- Education
- Scientific research
- Statistics
- Planning and reporting duty of an authority
- Development and innovation activities
- Knowledge management
- Steering and supervision of social and health care by authorities
Different types of data are available for different purposes:
- Individual-level, pseudonymised data is available for research, statistics, planning and reporting tasks of public authorities, and education.
- Anonymous, aggregated statistical data is available not only for the above-mentioned purposes, but also for development and innovation activities, knowledge management, and the steering and supervision of social and healthcare services.
In addition, wellbeing services counties and other service providers may use the data recorded in their own registers without a separate permit for purposes such as planning and evaluating their operations.
All data permit and data request decisions made by Findata are public. You can view them here: Issued permits
What types of data can be used with a permit from Findata?
Findata grants permits for the use of register-based data collected from various sources. This refers to information stored in registers maintained by public authorities, private service providers or other data processors.
Information about every Finnish resident is collected in different social and healthcare registers. In Finland, this data can be used for secondary purposes – for example, research aimed at improving public health and wellbeing.
We grant permits when data is needed from several public data controllers, private operators, Findata’s ready-made datasets or from the Kanta Services. Some data controllers have authorised Findata to issue permits on their behalf.
All permits comply with the data minimisation principle under the EU General Data Protection Regulation (GDPR): a permit can only be granted for data that is clearly and justifiably necessary for the stated purpose.
Before any data is released, it is pseudonymised. This means that directly identifying information – such as names or personal identity codes – is removed or replaced with a unique code, so that individuals cannot be directly identified.
Read more: Data
Can anyone get a permit to use social and health data?
The law does not specifically restrict who can apply for a permit to use social and health data. However, Findata does not grant permits to just anyone or for any purpose. A permit can only be issued for the purposes defined in the Act on the Secondary Use of Health and Social Data and for projects that meet the legal criteria for approval.
Each permit application is assessed individually. Before a permit is granted, the application undergoes a careful review. Under the EU General Data Protection Regulation (GDPR) and the data minimisation principle, a permit can only be granted for the use of data that is essential for the execution of the project.
Data permits are official administrative decisions. The decision process has two stages: the application handler acts as the presenter, and the Director of Findata or their deputy makes the final decision. The proposed decision does not always lead directly to a permit being granted: sometimes the application is returned for further preparation or requires modifications.
Read more: Conditions of data permit
Which laws regulate the secondary use of health and social data?
The secondary use of health and social data is governed by several laws that safeguard data protection and define the conditions under which the data may be processed.
The EU General Data Protection Regulation (GDPR) establishes the general principles for processing personal data across the EU. It is complemented by national legislation, such as the Act on the Secondary Use of Health and Social Data (the “Secondary Use Act”), which specifically regulates the secondary use of health and social data in Finland.
The Secondary Use Act centralises the issuance of data permits to Findata and defines in detail the permitted purposes for data use as well as the requirements for data security and oversight.
In the coming years, the European Health Data Space (EHDS) regulation will harmonise the use of health data and permit procedures for secondary use across the EU. EHDS will strengthen individuals’ rights to their data and promote the secure and efficient cross-border use of health data. The provisions concerning secondary use will apply starting in March 2029.
Other key laws include:
- Data Protection Act (Tietosuojalaki)
- Act on the Processing of Client Data in Healthcare and Social Welfare
- Medical Research Act
- Clinical Trials on Medicinal Products for Human Use Act
- Act on the Medical Use of Human Organs, Tissues and Cells
- Biobank Act
Read more:
What are the benefits of the secondary use of health and social data for citizens?
The secondary use of health and social data means using already collected client and patient data for purposes other than their original use, such as research, statistics, and service development.
When researchers, authorities and service providers are able to use reliable and comprehensive register data, it generates information that support decision-making and improve the quality of services. This leads to several concrete benefits for citizens:
- Better services and more effective care
- Data can be used to develop health and social services that better meet people’s needs.
- More effective medicines and health technology
- Extensive registry data supports medical research and the development of new treatments. It also enables the creation of health-promoting applications and supportive technologies.
- Safer and more agile tools for supervision
- Data can be used to monitor, for example, adverse effects of medicines and to improve oversight in healthcare.
- Smoother service processes
- Data enables the development of service systems that are more efficient and customer-oriented.
- Promoting public health and reducing wellbeing gaps
- Research-based information supports legislation and policymaking, helping to promote health and reduce inequality.
The secondary use of health and social data is strictly regulated. Citizens’ privacy is protected through measures such as pseudonymisation and secure processing environments.
See what types of projects Findata has granted permits for: Issued permits
How does the Secondary Use Act improve data protection?
The Act on the Secondary Use of Health and Social Data (also known as the Secondary Use Act) strengthens the protection of personal data by clearly defining how and under what conditions health and social data can be used for purposes other than their original use, such as research and statistics.
Prior to the implementation of the Secondary Use Act in 2019, the processing of data involved several risks:
- Permit applications were not centralised
- Permits were granted by individual data controllers, the Ministry of Social Affairs and Health, or the Finnish Institute for Health and Welfare (THL). Practices varied, and there was no consistent process.
- Data could be transferred on physical storage devices
- Datasets were sometimes delivered directly to permit holders via USB sticks or CDs. This made it impossible to ensure data security or monitor how the data was used.
- There was no way to monitor data usage afterwards
- There was no way to track whether datasets had been deleted after the permit expired.
The Act has enhanced data protection in several key ways:
- Centralised permit process at Findata
- Under the Act, all data permits are issued by Findata, the Finnish Health and Social Data Permit Authority. This has improved both data security and the protection of personal data.
- Centralised data combining ensures safer processing and enables more effective oversight.
- Pseudonymisation of datasets
- Datasets issued under the Act are pseudonymised, meaning direct identifiers are removed before the data is delivered to the permit holder.
- Pseudonymisation prevents the direct identification of individuals.
- Secure processing environment
- Data may only be analysed in a secure processing environment that has no direct internet access. These environments offer strong safeguards:
- Only users named in the permit may access the data
- Users log in using two-factor authentication
- External data cannot be uploaded to the environment
- Data cannot be exported without Findata’s review
- Access to the data is terminated once the data permit is no longer valid
- Data may only be analysed in a secure processing environment that has no direct internet access. These environments offer strong safeguards:
- Enhanced oversight
- Findata’s operations are overseen by the Parliamentary Ombudsman and the Data Protection Ombudsman
- Findata may request a statement from the Data Protection Ombudsman before granting a permit
- Findata submits an annual report to the Data Protection Ombudsman on the processing of social and health data and related logs
- The National Supervisory Authority for Welfare and Health (Valvira) monitors the security of the processing environments
How is Findata’s operation supervised?
Several authorities supervise Findata’s operation to ensure that the granting of data permits and the processing of data are carried out in accordance with the law.
- Data Protection Ombudsman
- Supervises the processing of personal data and ensures that Findata complies with data protection legislation.
- Receives an annual report from Findata on the processing of social and health data and the related log data.
- May issue statements at Findata’s request before a data permit is granted.
- Parliamentary Ombudsman
- Oversees the lawfulness of Findata’s activities.
- Valvira (The National Supervisory Authority for Welfare and Health)
- Supervises the secure operating environments where data granted by Findata are processed.
In addition, Findata’s operation is guided and developed by a steering group appointed by the Ministry of Social Affairs and Health (STM). The group includes representatives from STM and various data controllers.
How is the right to object implemented at Findata?
When you object to the secondary use of your data through Findata:
- Your request is recorded in the case management system maintained by the Finnish Institute for Health and Welfare (THL).
- Your data will be removed from datasets received by Findata based on your personal identity code. Therefore, we must retain and process your personal identity code to implement the request.
What is the EHDS?
The European Health Data Space (EHDS) is a regulation of the European Union that establishes a common framework for the use and exchange of health data in EU countries. The aim of the regulation is to strengthen citizens’ rights to their own electronic health data and to enable the secure cross-border secondary use of health data.
The EHDS regulation is similar to the current Finnish Secondary Use Act, but it also introduces changes. The regulation includes partly different purposes of use, some of which are reserved only for public or EU entities. In addition, new operating models will be introduced for processing data requests and permit applications.
The regulation entered into force in March 2025 and will be implemented gradually over the coming years. The parts concerning secondary use will begin to apply in March 2029.
What are the laws on which Findata bases the processing of personal data?
Findata’s legal basis for processing personal data are:
- Article 6, (1)(e) of the EU’s General Data Protection Regulation: processing is necessary for the performance of a task carried out in the public interest or in the exercise of official authority vested in the controller
- Article 4(1)(2) of the Data Protection Act: processing of data that is provided for by the law or that is directly attributable to the controller for the task prescribed by the law
We also process data belonging to special categories of personal data, formerly known as sensitive data. Such data includes, for example, a person’s health data.
The grounds for processing this kind of personal data are:
- Article 9(2)(g) of the EU General Data Protection Regulation: processing is necessary for the performance of a task carried out in the public interest or the exercise of public authority
- Section 6(1)(2) of the Data Protection Act: processing is necessary and proportionate for the performance of a task carried out in the public interest by a public authority
What is anonymisation and pseudonymisation?
Anonymisation means the transformation of personal data into a form that irreversibly prevents the identification of an individual person. This may mean, for example, removing direct identifiers and simplifying the data to a general level so that personal data cannot be reconstituted in any way.
Pseudonymisation refers to the transformation of personal data, for example into a coded form. In this case, names and personal identifiers can be removed and replaced by another unique identifier, i.e. a code. Often a code key is kept to restore direct personal data to the data. Pseudonymised data are still personal data.
Does Findata transfer data abroad?
Findata grants most permits to projects based in Finland. However, under the EU General Data Protection Regulation (GDPR), personal data must be able to move freely within the EU. This means that the permit holder may also be located in another EU or EEA country. Even in such cases, the data must be processed in an audited and secure environment, with access granted only to the individuals specified in the permit.
According to the Secondary Use Act, the secure processing environment must not be located outside the EU or EEA. Therefore, Findata does not, as a rule, transfer personal data outside the EU/EEA or to international organisations.
If data is to be transferred to or processed in countries outside the EEA (so-called third countries) a legal basis is required under Chapter V of the GDPR. It is important to note that processing personal data from outside the EEA is considered a data transfer, even if the data remains in a secure remote access environment.
Read more:
Does Findata sell my data?
Findata does not sell data. As the data permit authority, we grant fixed-term permits for the secondary use of social and health data only when the conditions set out in the Act on the Secondary Use of Health and Social Data are met.
Each permit is granted for a specific purpose, and it defines which individuals are allowed to process the pseudonymised dataset. Those who process the data must produce analysis results in anonymous form, so that no individual’s information or characteristics can be identified.
Findata is responsible for ensuring the anonymity of results, in accordance with the Secondary Use Act. This applies to all datasets covered by a permit.
When the permit expires, the permit holder’s access to the data is revoked and the dataset is destroyed.
Read more: Conditions of data permit
How can I object to the secondary use of my data?
Everyone has the right to their personal data, including the right to object to the processing of their data. Once you submit an objection request, Findata will no longer disclose your data for secondary use.
- The objection is valid indefinitely from the date it is processed.
- The objection is not retroactive: your data will not be removed from data resources that have already been disclosed to permit holders before the objection was submitted.
- You can submit the objection request via Findata’s e-service, by post or by visiting the Finnish Institute for Health and Welfare (THL) in person.
Instructions on how to exercise your rights: Your data rights
Please note that an objection submitted to Findata does not prevent other data controllers listed in the Act on the Secondary Use of Health and Social Data from disclosing your data for secondary purposes.
There is currently no centralised system in Finland that would allow you to object to the secondary use of your data in a way that would be binding on all controllers. Therefore, objections must be submitted separately to each controller.
- Read more: What data do my rights cover?
- Information on data controllers and the contents of their registers: Data
- Guidance from the Office of the Data Protection Ombudsman on how to object to the use of your data: If you do not want your data processed (tietosuoja.fi)
What is the difference between primary and secondary use of health and social data?
Primary use means the purpose for which the data was originally saved in the customer register and/or patient register.
The primary purpose may be, for example,
- examination, treatment and rehabilitation of the patient,
- the service received by a social welfare customer,
- or the processing of benefits by the Social Insurance Institution of Finland (Kela).
Secondary use means the use of the same data for purposes other than the primary use.
Legitimate secondary purposes of use include
- scientific research,
- statistics,
- development and innovation activities,
- education,
- knowledge management,
- steering and supervision by authorities and
- the planning and reporting duty of an authority.
Different purposes of use are subject to different regulations. Only aggregated statistics from which individuals cannot be identified may be obtained for development and innovation activities.
Explore studies utilising register data
Published research results
The table below contains information on publications that have used registry data authorised by Findata. Permit holders report their publications to Findata themselves.
Submit your publications here: Report published research results
Table updated: 18 November 2025
| Year of publication | Project name | Title of publication | Authors | Publication channel | DOI / Link to publication |
|---|---|---|---|---|---|
| 2025 | Ulkosynnytinsyövän leikkauskäytännöt – vaikutus leikkauskomplikaatioihin ja onkologiseen ennusteeseen | Electrothermal bipolar vessel sealing devices are associated with lower rates of postoperative complications compared to ultrasonic devices in vulvar cancer surgery. | Mörsky MK, Kaartinen IS, Nyberg RH | PLOS ONE, 20(10): e0335266 | https://doi.org/10.1371/journal.pone.0335266 |
| 2025 | Ulkosynnytinsyövän leikkauskäytännöt – vaikutus leikkauskomplikaatioihin ja onkologiseen ennusteeseen | Oncological outcomes, surgical margins, and adjuvant treatment delays in vulvar cancer patients with or without reconstruction during primary surgery. | Mörsky MK, Nyberg RH, Vuento MH, Staff S, Kaartinen IS | International Journal of Gynecological Cancer, 35(7):101942 | https://doi.org/10.1016/j.ijgc.2025.10194 |
| 2025 | REAL-WORLD EVIDENCE STUDY OF THE IMPACT OF ASCT AND NEW DRUG TREATMENTS ON MULTIPLE MYELOMA (MM) SURVIVAL AND COMORBIDITIES COMPARED TO non-MM CONTROL POPULATION IN FINLAND BETWEEN 2000-2020 | A real-world study on the impact of infection load on mortality in multiple myeloma patients in Finland. | Anttalainen A, Havula E, Kysenius K, Toppila I, Miettinen T, Lassenius M, Silvennoinen R, Partanen A, Putkonen M | Annals of Hematology, 104(4):2373–2385 | https://doi.org/10.1007/s00277-024-06101-3 |
| 2025 | Long Acting Injectable Buprenorphine Use in Finland | Early experiences of buprenorphine long-acting injection in Finland: a retrospective cohort study. | Partanen M, Saarenpää T, Prami T, Iso-Mustajärvi I, Vehkala M, Landelius Torper O, Ryder B, Simojoki K | Poster, International Society of Addiction Medicine (ISAM) Annual Conference, Hamburg, Germany | |
| 2025 | Jakavi (ruxolitinib) treatment outcomes in acute graft versus host disease (GvHD) in real-world setting in Helsinki and Turku University Hospitals | Ruxolitinib treatment outcomes in acute graft-versus-host disease (aGvHD) in a real-world setting in Finland. | Martelin E, Kuikka A, Rajala H, Ruohonen T, Mönkkönen H, Vikkula J, Uusi-Rauva K, Salmenniemi U, Itälä-Remes M | Annals of Hematology, 104, 3451–3458 (2025) | https://doi.org/10.1007/s00277-025-06439-2 |
| 2025 | Multiple Myeloma (MM) – Characteristics, treatment praxis, Healthcare Resource Utilization (HCRU) and utilization of machine learning tools to identify novel risk factors | Evolution of treatment practices and outcomes in multiple myeloma during 2013–2022: a Finnish real-world registry study. | Partanen A, Waltari M, Vikkula J, Mattila R, Närhi K, Eeva J, Putkonen M | Acta Oncologica, 64:598–606 | https://doi.org/10.2340/1651-226X.2025.42647 |
| 2025 | Burden of illness in asthma and COPD | Burden of asthma by severity and exacerbation frequency among adult patients naive to biologic asthma therapy: a Finnish cohort study. | Kankaanranta H, Viinanen A, Klåvus A, Lassenius MI, Olsen HH, Nieminen K, Lyly A, Kauppi P, Lehtimäki L | Journal of Allergy and Clinical Immunology: Global, 4(2):100453 | https://doi.org/10.1016/j.jacig.2025.100453 |
| 2025 | Keskivaikean ja vaikean atooppisen ekseeman hoito ja dupilumabin käyttö Suomessa | Characterizing patients and treatment patterns in moderate-to-severe atopic dermatitis in Finland: a population-based study using national health data. | Remitz A, Peltonen EJ, Korhonen L, Nortamo P, Iso-Mustajärvi I, Prami T, Oinonen L, Gittens B, Von Arx LB, Porsdal V | Acta Dermato-Venereologica, 105, adv41244 | https://pubmed.ncbi.nlm.nih.gov/40271985/ |
| 2025 | Association between dental fear and the dental attendance of the family | Changes in oral health-related quality of life according to public oral health procedures in parents of young children from the FinnBrain Birth Cohort Study. | Palo K, Tolvanen M, Suominen A, Karlsson H, Karlsson L, Lahti S | Community Dentistry and Oral Epidemiology (Wiley), 53: 382-388. | https://onlinelibrary.wiley.com/doi/10.1111/cdoe.13039 |
| 2025 | Disease management, outcomes, and health care resource use associated with real-life clinical practice of diabetes and diabetic kidney disease in Finland (FinDIABREN-RWE) | Diabeteksen munuaistaudin toteaminen on puutteellista Keusoten alueella. | Laine MK, Haapala M, Uusi-Rauva K, Aakko J, Pentikäinen M, Mikkola K, Halonen N, Pulkki K, Säävuori N, Groop P-H, Metsärinne K | Suomen Lääkärilehti, 80:e43390 | https://www.laakarilehti.fi/e43390 |
| 2025 | FINHRBC – epidemiology and clinical characteristics of hormone receptor positive breast cancer patients in Finland | Real-world observational study of incidence and outcomes in an HR+/HER2– early breast cancer population with high risk of recurrence in Finland. | Singh, R., Tuominen, S., Lassenius, M.I. et al. | Oncology and Therapy 13, 185–200 (2025) | https://doi.org/10.1007/s40487-024-00324-0 |
| 2025 | Patient characteristics and treatment landscape of metastatic castration resistant prostate cancer in Finland | Real-world treatment patterns and survival outcomes in men with metastatic castration-resistant prostate cancer in Finland: a national, population-based cohort study. | Rannikko A, Hölsä O, Ågesen T, Ekman M, Mattila R | Acta Oncologica, 64:173–178 | https://doi.org/10.2340/1651-226X.2025.42173 |
| 2025 | The SORREL study – Prevalence, Characteristics, and Burden of Nasal Polyps in Chronic Rhinosinusitis Patients in Finland | Predictors of revision endoscopic sinus surgery in Finnish patients with chronic rhinosinusitis with nasal polyps. | Toppila-Salmi S, Lyly A, Simin J, Aakko J, Haugom Olsen H, Lehtimäki L | Clinical and Translational Allergy, 2025;e70032 | https://onlinelibrary.wiley.com/doi/10.1002/clt2.70032 |
| 2025 | SOTE-PALVELUT LÄPINÄKYVIKSI: Palvelu- ja tietointegraatio yhtenäisen tietomallin ja yhdistetyn tietopohjan avulla | Changes in depression medication following the initial assessment by specialised psychiatry services in the Helsinki-Uusimaa Region | Juntura J, Näätänen P, Joffe G, Ekelund J, Leskelä R-L, Ito T, Rive B, Godinov Y, Eriksson I, Torkki P | EPA 2025 (Conference abstract) | |
| 2025 | Attention deficit hyperactivity disorder (ADHD) care in Finland | Use of Antidepressants Decreased After Initiation of ADHD Treatment in Adults—A Finnish Nationwide Register Study Describing Use of ADHD and Non-ADHD Medication in People With and Without ADHD | Westman E, Prami T, Kallio A, Iso-Mustajärvi I, Jukka J, Raittinen P, Korhonen MJ, Puustjärvi A, Leppämäki S | Acta Psychiatrica Scandinavica 152, no. 3 (2025): 203–215 | https://doi.org/10.1111/acps.70007 |
| 2025 | Työkyvyn tila Suomessa | Työkyvyn ja työhön osallistumisen kokonaisvaltainen tarkastelu ja palvelu- ja etuusjärjestelmän reunaehdot : Tutkimustuloksia päätöksenteon tueksi | Henriksson M, Mesiäislehto M, Ahola E, Joensuu M, Kärkkäinen S, Laaksonen J, Saikku P, Siltala V, Turunen J | Sosiaali- ja terveysministeriön raportteja ja muistioita 2025:5 | http://urn.fi/URN:ISBN:978-952-00-8681-7 |
| 2025 | Työkyvyn tila Suomessa | Tutkimus: työkykyä on tuettava työelämän muutoksissa ennen kuin työkyvyttömyysriskejä ilmaantuu | Sosiaali- ja terveysministeriö | Sosiaali- ja terveysministeriö | https://stm.fi/-/tutkimus-tyokykya-on-tuettava-tyoelaman-muutoksissa-ennen-kuin-tyokyvyttomyysriskeja-ilmaantuu |
| 2024 | REAL-WORLD EVIDENCE STUDY OF THE IMPACT OF ASCT AND NEW DRUG TREATMENTS ON MULTIPLE MYELOMA (MM) SURVIVAL AND COMORBIDITIES COMPARED TO non-MM CONTROL POPULATION IN FINLAND BETWEEN 2000-2020 | Comorbidities and survival of multiple myeloma patients diagnosed in Finland between 2000 and 2021. | Kysenius K, Anttalainen A, Toppila I, Miettinen T, Lassenius M, Lievonen J, Partanen A, Silvennoinen R, Putkonen M | Annals of Hematology, 103, 2931–2943 (2024) | https://doi.org/10.1007/s00277-024-05865-y |
| 2024 | Multiple Myeloma (MM) – Characteristics, treatment praxis, Healthcare Resource Utilization (HCRU) and utilization of machine learning tools to identify novel risk factors | A real-world study of multiple myeloma patients with at least 3 prior treatment lines and triple class exposed disease in Finland: outcomes and need for healthcare resource use. | Putkonen M, Kivioja A, Vikkula J, Waltari M, Mattila R, Närhi K, Eeva J, Partanen A | Value in Health, 27(12):S2 | https://www.ispor.org/heor-resources/presentations-database/presentation/euro2024-4018/143359 |
| 2024 | Raskauden aikaisen metformiini-altistuksen pitkäaikaiset vaikutukset lapseen Suomessa – CLUE-tutkimus | Metformin in pregnancy and risk of adverse long-term outcomes: a register-based cohort study. | Brand KMG, Saarelainen L, Sonajalg J, Boutmy E, Foch C, Vääräsmäki M, et al. | BMJ Open Diabetes Research & Care, 10(1):e002363 | https://drc.bmj.com/content/10/1/e002363 |
| 2024 | Raskauden aikaisen metformiini-altistuksen pitkäaikaiset vaikutukset lapseen Suomessa – CLUE-tutkimus | Metformin in pregnancy and risk of abnormal growth outcomes at birth: a register-based cohort study. | Brand KM, Thoren R, Sõnajalg J, Boutmy E, Foch C, Schlachter J, et al. | BMJ Open Diabetes Research & Care, 10(6):e003056 | https://drc.bmj.com/content/10/6/e003056 |
| 2024 | Endometrial Cancer Real World Evidence Study in Finland: A Real-World study on patient characteristics, treatment patterns and outcomes of recurrent or advanced endometrial cancer patients in Finland | Healthcare resource utilisation (HCRU) and medical costs among patients with endometrial cancer in a real-world setting in Finland (the FIRE study). | Mascialino B, Aakko J, Kysenius K, Tuominen S, Idänpään-Heikkilä J, Käkelä S, Tikka S, Schneider D, Hietanen S, Lassus H, Auranen A | Poster, ISPOR Europe Meeting, Barcelona, Spain | |
| 2024 | TYÖOTE – HANKKEEN VAIKUTTAVUUSTUTKIMUS – Rekisteripohjainen arviointitutkimus vastuullisen asiakasohjausmallin etuisuusmaksu- ja tuottavuusvaikutuksista | Effectiveness of the Coordinated Return to Work model after orthopaedic surgery for lumbar discectomy and hip and knee arthroplasty: a register-based study. | Lavikainen P, Heiskanen J, Jalkanen K, Lehtimäki A-V, Vehkala S, Kangas P, Husman K, Vohlonen I, Martikainen J | Occupational and Environmental Medicine, 81:150–157 | https://doi.org/10.1136/oemed-2023-109276 |
| 2024 | Työkykyriskin ennustaminen ja korkeariskisten henkilöiden ryhmittely ennaltaehkäisevän työterveyshuollon tueksi | Associations of depressive symptoms and psychosocial working conditions with sickness absences in a Finnish cohort of 11,495 employees. | Anttila A, Nuutinen M, Van Gils M, Pekki A, Sauni R | Preventive Medicine Reports, 47 | https://authors.elsevier.com/sd/article/S2211-3355(24)00314-0 |
| 2024 | Kystisen fibroosin epidemiologia ja hoito Suomessa | Cystic fibrosis patient characteristics and healthcare resource utilisation in Finland using linked registries. | Malmivaara K, Pölkki M, Prami T, Raittinen P, Heikkilä E, Aalto A, Dunder T, Elenius V, Sandström K, McGarry LJ | Heliyon, 10:e33439 | https://www.cell.com/action/showPdf?pii=S2405-8440%2824%2909470-2 |
| 2024 | Ympäristö, geenit ja syöpäriski: seurantatutkimuksia Suomalaisessa kaksoskohortissa. | Novel epigenetic biomarkers for hematopoietic cancer found in twins. | Clemmensen SB, Frederiksen H, Mengel-From J, Heikkinen A, Kaprio J, Hjelmborg JV | Acta Oncologica, 63:710–717 | https://doi.org/10.2340/1651-226X.2024.40700 |
| 2024 | Finnish Diabetes Control study – FinDiCon | Increasing clinical inertia in basal insulin initiations in people living with type 2 diabetes in Finland | 23rd Nordic Congress of General Practice 2024; Turku, Finland; 11–14 June 2024 | ||
| 2024 | Finnish Diabetes Control study – FinDiCon | Trends in demographics and diabetes-related complications in people living with type 1 diabetes between 2014 and 2021 in Finland | 60th Annual Meeting European Association for the Study of Diabetes; Madrid, Spain; 10–13 September 2024 | ||
| 2024 | Sähköisten reseptien hyödyt ja kustannukset | Information Technology, Improved Access, and Use of Prescription Drugs | Böckerman P, Kortelainen M, Laine LT, Nurminen M, Saxell T | Journal of the European Economic Association 23(1):396–430 | https://doi.org/10.1093/jeea/jvae034 |
| 2024 | Sähköisten reseptien hyödyt ja kustannukset | Antidepressant Persistence Before and After the Introduction of Online Renewal | Kovalainen O-T | Master’s thesis, University of Helsinki | https://ethesis.helsinki.fi/repository/handle/123456789/2/browse?type=author&value=Kovalainen%2C+Olli-Tuomas |
| 2024 | lkääntyneiden sydän- ja verisuonisairastuvuus ja kuolleisuus – seurantatutkimus | New reference limits for cardiac troponin T and N-terminal b-type natriuretic propeptide in elders | Heikkilä E, Katajamäki T, Salminen M, Irjala K, Viljanen A, Koivula M-K, Pulkki K, Isoaho R, Kivelä S-L, Viitanen M, Löppönen M, Vahlberg T, Viikari L | Clinica Chimica Acta 2024;556:117844 | https://doi.org/10.1016/j.cca.2024.117844 |
| 2024 | lkääntyneiden sydän- ja verisuonisairastuvuus ja kuolleisuus – seurantatutkimus | Predicting successful ageing among older adults seems possible even as far as two decades ahead | Viljanen A, Salminen M, Irjala K et al. | BMC Geriatrics 2024;24:481 | https://doi.org/10.1186/s12877-024-02481-5 |
| 2024 | SOTE-PALVELUT LÄPINÄKYVIKSI: Palvelu- ja tietointegraatio yhtenäisen tietomallin ja yhdistetyn tietopohjan avulla | Societal costs of depression and outcomes of care in Finland | Näätänen P, Juntura J, Joffe G, Ekelund J, Nuutinen M, Leskelä R-L, Ito T, Rive B, Godinov Y, Eriksson I, Torkki P | ICHOM 2024 (Conference abstract) | |
| 2024 | Elämänkokemukset, ylisukupolviset prosessit ja perinataalivaiheen sosioekonomiset terveyserot (Life course experiences, intergenerational processes, and socioeconomic health inequalities in perinatal period) | Seasonality of Birth Weight in Singleton Full-term Births in Finland | Orderud H., Eskelinen N., Lindberg M. | Finnish Yearbook of Population Research, 57, 21–46 | https://doi.org/10.23979/fypr.136379 |
| 2024 | Elämänkokemukset, ylisukupolviset prosessit ja perinataalivaiheen sosioekonomiset terveyserot (Life course experiences, intergenerational processes, and socioeconomic health inequalities in perinatal period) | Low and very low birthweight disadvantage in compulsory education achievement and transition to upper secondary education | Lindberg M | . Child Care Health Dev, 50(2):e13243 | https://doi.org/10.1111/cch.13243 |
| 2024 | Kasvaingeenitutkimus | Cancer incidence following non-neoplastic medical conditions | Sipilä LJ, Tanskanen T, Heikkinen S, Seppä K, Aavikko M, Ravantti J, Aaltonen LA, Pitkäniemi J | Acta Oncologica, 63(1), 841–849 | https://doi.org/10.2340/1651-226X.2024.40757 |
| 2024 | Kasvaingeenitutkimus | Lynch syndrome-associated and sporadic microsatellite unstable colorectal cancers | Martin S, Katainen R, Taira A, Välimäki N, Ristimäki A, Seppälä T, Renkonen-Sinisalo L, Lepistö A, Tahkola K, Mattila A, Koskensalo S, Mecklin JP, Rajamäki K, Palin K, Aaltonen LA. | Human Molecular Genetics, 33(21):1858–1872 | https://doi.org/10.1093/hmg/ddae124 |
| 2024 | Kasvaingeenitutkimus | Non-stem cell lineages as an alternative origin of intestinal tumorigenesis | Verhagen MP., Joosten R., Schmitt M., Välimäki N., ym. | Nat Genet 56, 1456–1467 | https://doi.org/10.1038/s41588-024-01801-y |
| 2024 | Kasvaingeenitutkimus | Detection of a major Lynch Syndrome-causing MLH1 founder variant in a large-scale genotyped cohort | Sipilä LJ ym. | Familial Cancer 23, 647–652 | https://doi.org/10.1007/s10689-024-00400-4 |
| 2024 | Kasvaingeenitutkimus | Genome-wide somatic mutation analysis of sinonasal adenocarcinoma with and without wood dust exposure | Sipilä LJ ym. | Genes and Environ 46, 12 | https://doi.org/10.1186/s41021-024-00306-8 |
| 2024 | Trends in operative delivery rates in Estonia and Finland. | Caesarean section and operative vaginal delivery in Estonia and Finland from 1992 to 2016 | Sildver K., Veerus P., Gissler M., Lang K., Pisarev H. | European Journal of Public Health, 34(6):1205–1209 | https://doi.org/10.1093/eurpub/ckae162 |
| 2024 | Reseptien uudistaminen ja lääkehoidon seuranta – Rekisteritutkimus potilasta kohtaamatta uudistetuista lääkityksistä ja terveydenhuollon palvelujen käytöstä | Register-based study on prescription renewal without the prescriber meeting the patient | Rönngård-Jalkanen A., Aarnio E., Saastamoinen L., Timonen J. | Basic Clin Pharmacol Toxicol, 135(3): 321-333 | https://doi.org/10.1111/bcpt.14049 |
| 2024 | Työkyvyn tila Suomessa | Työkyky ja työhön osallistuminen – tuloksia työikäisen väestön ryhmittelystä | Turunen J, Siltala V, Henriksson M, Ahola E, Joensuu M | Työterveyslaitos, Työelämätieto-palvelu | https://www.tyoelamatieto.fi/fi/aineistot/tyokyky-ja-tyohon-osallistuminen-tuloksia-tyoikaisen-vaeston-ryhmittelysta |
| 2024 | Työkyvyn tila Suomessa | Työkyky ja työhön osallistuminen – vertailutuloksia työikäisen väestön ryhmittelystä | Turunen J, Siltala V, Henriksson M, Ahola E, Joensuu M | Työterveyslaitos, Työelämätieto-palvelu | https://www.tyoelamatieto.fi/fi/analyysit/tyokyky-ja-tyohon-osallistuminen-vertailutuloksia-tyoikaisen-vaeston-ryhmittelysta |
| 2024 | Työkyvyn tila Suomessa | Työikäiset ryhmiteltiin uudella tavalla – ryhmä- ja hyvinvointialuekohtaiset erot työhön osallistumisessa isoja | Työterveyslaitos | Työterveyslaitos | https://www.ttl.fi/ajankohtaista/tiedote/tyoikaiset-ryhmiteltiin-uudella-tavalla-ryhma-ja-hyvinvointialuekohtaiset-erot-tyohon |
| 2024 | Työkyvyn tila Suomessa | Työkyky ja työhön osallistuminen | Henriksson M | HVA työikäiset verkosto | |
| 2024 | Työkyvyn tila Suomessa | Työkyky ja työhön osallistuminen – vertailutuloksia työikäisen väestön ryhmittelystä | Turunen J | Kela seminaari | |
| 2024 | Työkyvyn tila Suomessa | Työkyky ja työhön osallistuminen | Henriksson M | Kela ja TTL verkkoseminaari | https://www.kela.fi/yhteistyokumppanit-koulutustallenteet#verkkoseminaari-1752024-kohti-yhteista-ymmarrysta-tyokyvysta-ja-sen-tukemisesta |
| 2024 | Työkyvyn tila Suomessa | Työkyky ja työhön osallistuminen | Henriksson M | THL seminaari | |
| 2024 | Työkyvyn tila Suomessa | Work Ability and Work Participation: Findings from a Register Study on Finland’s Working-Age Population | Turunen J, Siltala V, Henriksson M, Joensuu M, Ahola E | Nordic Working Life Conference, Roskilde, Denmark | |
| 2024 | Työkyvyn tila Suomessa | From Work Ability to Work Potential | Henriksson M, Joensuu M, Turunen J, Ahola E, Siltala V | 16th ESA Conference Porto, Portugal | |
| 2024 | Työkyvyn tila Suomessa | Mielenterveys sosiaali- ja terveysalalla sekä taide-, kulttuuri- ja tapahtuma-aloilla | Ahola E, Ropponen A | Työterveyslaitos, Työelämätieto-palvelu | https://www.tyoelamatieto.fi/fi/aineistot/mielenterveys-sosiaali-ja-terveysalalla-seka-taide-kulttuuri-ja-tapahtuma-aloilla |
| 2024 | Työkyvyn tila Suomessa | Sosiaali- ja terveysalalla sekä taide-, kulttuuri- ja tapahtuma-aloilla työskennelleiden mielenterveyden ja poissaolojen kehitys on vastaava kuin muilla aloilla | Ropponen A, Varje P | Työterveyslaitos, Työelämätieto-palvelu | https://www.tyoelamatieto.fi/fi/analyysit/sosiaali-ja-terveysalalla-seka-taide-kulttuuri-ja-tapahtuma-aloilla-tyoskennelleiden-mielenterveyden-ja-poissaolojen-kehitys-on-vastaava-kuin-muilla-aloilla |
| 2024 | Työkyvyn tila Suomessa | The role of mental health related healthcare use on work participation among unemployed | Salonen L, Solovieva S, Junna L, Pitkänen J, Kauhanen A, Leinonen T | 3rd International PEROSH Conference on Prolonging Working Life | |
| 2024 | Työkyvyn tila Suomessa | The role of mental health related healthcare use in employment and benefit use after unemployed | Salonen L, Solovieva S, Junna L, Pitkänen J, Kauhanen A, Leinonen T | European Journal of Public Health | https://doi.org/10.1093/eurpub/ckae144.726 |
| 2024 | Työkyvyn tila Suomessa | Hyvinvointialue työhön osallistumisen ekosysteemissä | Henriksson M, Joensuu M, Turunen J, Ahola E, Ervasti J, Siltala V | Työelämän tutkimuspäivät 2024 | |
| 2024 | Työkyvyn tila Suomessa | Työkyky ja työhön osallistuminen – vertailutuloksia työikäisen väestön ryhmittelystä | Turunen J, Siltala V, Ahola E, Henriksson M, Ahtinen S, Ervasti J, Joensuu M | Työelämän tutkimuspäivät 2024 | |
| 2024 | Työkyvyn tila Suomessa | The role of mental health related healthcare use in employment and benefit use after unemployed | Salonen L, Solovieva S, Junna L, Pitkänen J, Kauhanen A, Leinonen T | European Public Health Conference | |
| 2024 | Työkyvyn tila Suomessa | Työkyky ja työhön osallistuminen: Tuloksia ja havaintoja työkykyohjelman laajennoksen tutkimusosuudesta | Henriksson M, Joensuu M, Turunen J, Ahola E, Ervasti J, Siltala V | THL seminaari | https://innokyla.fi/sites/default/files/2024-11/Mikko%20Henriksson%20s%20pidennetty.pdf |
| 2024 | Työkyvyn tila Suomessa | Työikäisten työkyky ja työhön osallistuminen | Henriksson M, Siltala V | THL seminaari | https://innokyla.fi/sites/default/files/2024-12/TTL%20webinaari%203.12.2024.pdf |
| 2023 | FinMDS | Characteristics, treatment and outcomes of myelodysplastic syndrome in two Finnish hospital districts. | Tuominen S, Miettinen T, Dünweber C | medRxiv 2023.10.06.23296265 | https://doi.org/10.1101/2023.10.06.23296265 |
| 2023 | Ympäristö, geenit ja syöpäriski: seurantatutkimuksia Suomalaisessa kaksoskohortissa. | The association between night shift work and breast cancer risk in the Finnish twins cohort | Schernhammer E, Bogl L, Hublin C, Strohmaier S, Zebrowska M, Erber A, Haghayegh S, Papantoniou K, Ollikainen M, Kaprio J | Eur J Epidemiol. 38(5):533-543 | https://doi.org/10.1007/s10654-023-00983-9 |
| 2023 | Finnish Diabetes Control study – FinDiCon | Alle 60-vuotiaiden tyypin 2 diabeteksen hoitotasapaino on keskimääräistä huonompi | Vessari H, Luoto H, Aalto A, Peltonen E. J, Iso-Mustajärvi I, Raittinen P, Prami T, Saraheimo M, Valle T.T, Saukkonen T | Lääkärilehti 2023 | https://www.laakarilehti.fi/tieteessa/alkuperaistutkimukset/alle-60-vuotiaiden-tyypin-2-diabeteksen-hoitotasapaino-on-keskimaaraista-huonompi/ |
| 2023 | Valinnanvapaus ja kilpailu julkisessa erikoissairaanhoidossa | Improving Performance Through Allocation and Competition: Evidence from a Patient Choice Reform | Kortelainen M, Laine LT, Lavaste K, Saxell T, Siciliani L | VATT Working Papers 156 | https://vatt.fi/julkaisu?pubid=URN%3ANBN%3Afi-fe20231003138612 |
| 2023 | lkääntyneiden sydän- ja verisuonisairastuvuus ja kuolleisuus – seurantatutkimus | A novel easy-to-use index to predict institutionalization and death in older population – a 10-year population-based follow-up study | Heikkilä E, Salminen M, Viljanen A, Katajamäki T, Koivula M-K, Pulkki K, Isoaho R, Kivelä S-L, Viitanen M, Löppönen M, Vahlberg T, Viikari L, Irjala K | BMC Geriatrics 2023;23:80 | https://doi.org/10.1186/s12877-023-03760-1 |
| 2023 | lkääntyneiden sydän- ja verisuonisairastuvuus ja kuolleisuus – seurantatutkimus | Re-examination of successful agers with lower biological than chronological age still after a 20-year follow-up period | Viljanen A, Salminen M, Irjala K, Korhonen P, Vahlberg T, Viitanen M, Löppönen M, Viikari L. | BMC Geriatrics 2023;23:128 | https://doi.org/10.1186/s12877-023-03844-y |
| 2023 | Economic burden of medicines on households: De-commodification and re-commodification (DE-RE) | Austerity, economic hardship and access to medications: a repeated cross-sectional population survey study, 2013–2020 | Aaltonen K | J Epidemiol Community Health 2023;77:160-167 | https://doi.org/10.1136/jech-2022-219706 |
| 2023 | Economic burden of medicines on households: De-commodification and re-commodification (DE-RE) | Lääkkeistä tinkiminen yleistyi hallituksen kovien säästötoimien aikaan | Aaltonen K | INVEST Blog | https://blogit.utu.fi/invest/2023/01/31/laakkeista-tinkiminen-yleistyi-hallituksen-kovien-saastotoimien-aikaan/ |
| 2023 | Elämänkokemukset, ylisukupolviset prosessit ja perinataalivaiheen sosioekonomiset terveyserot (Life course experiences, intergenerational processes, and socioeconomic health inequalities in perinatal period) | Birth Weight, Maternal Education, and NEET Status in Young Adulthood: Evidence Using Sibling Fixed-effects | Eskelinen N., Salonen L., Kotimäki S., Lindberg M., Härkönen J. | INVEST Working Paper 79, SocArXiv | https://doi.org/10.31235/osf.io/epfbz |
| 2023 | Elämänkokemukset, ylisukupolviset prosessit ja perinataalivaiheen sosioekonomiset terveyserot (Life course experiences, intergenerational processes, and socioeconomic health inequalities in perinatal period) | Low and Very Low Birthweight Disadvantage in Compulsory Education Achievement… | Lindberg M | INVEST Working Paper 76, SocArXiv | https://doi.org/10.31235/osf.io/dk369 |
| 2023 | Trends in operative delivery rates in Estonia and Finland. | Cesarean section trends from 1992 to 2016 in Estonia and Finland | Sildver K., Veerus P., Lang K., Pisarev H., Gissler M. | Acta Obstet Gynecol Scand. 2023; 102: 1007-1013 | https://doi.org/10.1111/aogs.14609 |
| 2023 | Entisten huippu-urheilijoiden sairastuvuus- ja kuolleisuustutkimus; fyysisesti aktiivisen elämäntavan pitkäaikaisvaikutukset terveyteen, toimintakykyyn ja kansansairauksien riskitekijöihin. | Dementia in former amateur and professional contact sports participants: population-based cohort study, systematic review, and meta-analysis | Batty GD, Frank P, Kujala UM, Sarna SJ, Valencia-Hernández CA, Kaprio J | eClinicalMedicine, Volume 61, 102056 | https://doi.org/10.1016/j.eclinm.2023.102056 |
| 2023 | Entisten huippu-urheilijoiden sairastuvuus- ja kuolleisuustutkimus; fyysisesti aktiivisen elämäntavan pitkäaikaisvaikutukset terveyteen, toimintakykyyn ja kansansairauksien riskitekijöihin. | Suicide and depression in former contact sports participants: population-based cohort study, systematic review, and meta-analysis | Batty GD, Frank P, Kujala UM, Sarna SJ, Kaprio J | EClinicalMedicine, Volume 60, 102026 | https://doi.org/10.1016/j.eclinm.2023.102026 |
| 2022 | Ympäristö, geenit ja syöpäriski: seurantatutkimuksia Suomalaisessa kaksoskohortissa. | Differences in DNA Methylation-Based Age Prediction Within Twin Pairs Discordant for Cancer | Bode HF, Heikkinen A, Lundgren S, Kaprio J, Ollikainen M | Twin Res Hum Genet. 25(4-5):171-179 | https://doi.org/10.1017/thg.2022.32 |
| 2022 | Sähköisten reseptien hyödyt ja kustannukset | Information Integration, Coordination Failures, and Quality of Prescribing | Böckerman P, Laine LT, Nurminen M, Saxell T | The Journal of Human Resources (published ahead of print December 7, 2022) | https://jhr.uwpress.org/content/early/2022/12/01/jhr.0921-11910R2 |
| 2022 | lkääntyneiden sydän- ja verisuonisairastuvuus ja kuolleisuus – seurantatutkimus | Ceramides and phosphatidylcholines associate with cardiovascular diseases in the elderly | Katajamäki T, Koivula M-K, Hilvo M, Lääperi M, Salminen M, Viljanen A, Heikkilä E, Löppönen M, Iso-aho R, Kivelä S-L, Jylhä A, Viikari L, Irjala K, Pulkki K, Laaksonen R | Clin Chem 2022. | https://doi.org/10.1093/clinchem/hvac158 |
| 2022 | Kehitysvammaisten lääkehoito ja asumispalvelut Suomessa. | Medicine use in people with intellectual disabilities: a Finnish nationwide register study | Nurminen F, Rättö H, Arvio M, Teittinen A, Vesala H. T., Saastamoinen L. | Journal of Intellectual Disability Research, 67: 1291–1305 | https://doi.org/10.1111/jir.12988 |
| 2022 | Uudenlaisen, systeemisen lääkehoidon persistenssi ja adherenssi keskivaikean tai vaikean läiskä- tai nivelpsoriaasin hoidossa – Rekisteripohjainen kohorttitutkimus Suomessa ja Ruotsissa | Persistence of advanced systemic pharmacological treatment of moderate-to-severe psoriasis among bio-naïve patients | G. Tskhvarashvili, K. Aher, I. Sveide, U. Katus, A. Westerlund, F. Hoti, C. Wennerström, F. Hassan, J. Lee, C. Hermanrud, I. Johnsson, A. Passey, R. Nissinen, S. Polesie, T. Mälkönen, L. Saarelainen | J Eur Acad Dermatol Venereol. 2025; 39(Suppl. 1): 50–64 | https://onlinelibrary.wiley.com/doi/10.1111/jdv.20198 |
| 2022 | Long Acting Injectable Buprenorphine Use in Finland | Early experience of buprenorphine long-acting injection in Finland: a retrospective cohort study | 15th European Congress on Heroin Addiction, Pisa | ||
| 2022 | Entisten huippu-urheilijoiden sairastuvuus- ja kuolleisuustutkimus; fyysisesti aktiivisen elämäntavan pitkäaikaisvaikutukset terveyteen, toimintakykyyn ja kansansairauksien riskitekijöihin. | Longitudinal Associations of High-Volume and Vigorous-Intensity Exercise With Hip Fracture Risk in Men | Korhonen MT, Kujala UM, Kettunen J, Korhonen OV, Kaprio J, Sarna S, Törmäkangas T | J Bone Miner Res, (8):1562-1570 | https://doi.org/10.1002/jbmr.4624 |
| 2021 | lkääntyneiden sydän- ja verisuonisairastuvuus ja kuolleisuus – seurantatutkimus | A practical laboratory index to predict institutionalization and mortality – an 18-year population-based follow-up study | Heikkilä E, Salminen M, Viljanen A, Katajamäki T, Koivula M-K, Pulkki K, Isoaho R, Kivelä S-L, Viitanen M, Löppönen M, Vahlberg T, Viikari L, Irjala K | BMC Geriatrics, 21, 139 (2021) | https://doi.org/10.1186/s12877-021-02077-1 |
| 2021 | lkääntyneiden sydän- ja verisuonisairastuvuus ja kuolleisuus – seurantatutkimus | Subjective and objective health predicting mortality and institutionalization: an 18-year population-based follow-up study | Viljanen A, Salminen M, Irjala K, Heikkilä E, Isoaho R, Kivelä S-L, Korhonen P, Vahlberg T, Viitanen M, Wuorela M, Löppönen M, Viikari L. | BMC Geriatrics 2021;21:358 | https://doi.org/10.1186/s12877-021-02311-w |
| 2021 | lkääntyneiden sydän- ja verisuonisairastuvuus ja kuolleisuus – seurantatutkimus | Chronic conditions and multimorbidity associated with institutionalization among Finnish community-dwelling older people | Viljanen A, Salminen M, Irjala K, Heikkilä E, Isoaho R, Kivelä S-L, Korhonen P, Vahlberg T, Viitanen M, Wuorela M, Löppönen M, Viikari L | Eur Geriatr Med 2021. | https://doi.org/10.1007/s41999-021-00535-y |
| 2021 | Älykäs luu – Koneoppimiseen perustuva DXA-kuvien analyysi potilaiden diagnostiikassa. | Detecting pathological features and predicting fracture risk from dual-energy X-ray absorptiometry images using deep learning | Nissinen T, Suoranta S, Saavalainen T, Sund R, Hurskainen O, Rikkonen T, Kröger H, Lähivaara T, Väänänen SP | Bone reports 2021 101070 | https://doi.org/10.1016/j.bonr.2021.101070 |
| 2020 | Valinnanvapaus ja kilpailu julkisessa erikoissairaanhoidossa | Effects of Maternity Ward Closures on Maternal Health in Finland | Hägg M | University of Eastern Finland, Master’s thesis | https://erepo.uef.fi/bitstream/handle/123456789/23053/urn_nbn_fi_uef-20200932.pdf |
| 2020 | Sähköisten reseptien hyödyt ja kustannukset | Information Integration, Coordination Failures, and Quality of Prescribing | Böckerman P, Laine LT, Nurminen M, Saxell T | VATT Working Papers 135 | https://vatt.fi/julkaisu?pubid=URN%3AISBN%3A978-952-274-260-5 |
| 2020 | lkääntyneiden sydän- ja verisuonisairastuvuus ja kuolleisuus – seurantatutkimus | Frailty, walking ability and self-rated health predicting institutionalization; an 18-year follow-up among Finnish community-dwelling older people | Viljanen A, Salminen M, Korhonen P, Irjala K, Wuorela M, Isoaho R, Kivelä S-L, Viitanen M, Löppönen M, Viikari L | Aging Clin Exp Res 2020 | https://doi.org/10.1007/s40520-020-01551-x |
| 2020 | Työkyvyn tila Suomessa | Labor Market Participation Before and After Long-Term Part-Time Sickness Absence in Finland: A Population-Based Cohort Study | Ervasti J, Kausto J, Koskinen A, Pentti J, Vahtera J, Joensuu M, Turunen J, Oksanen T, Kivimäki M | Journal of Occupational and Environmental Medicine | https://journals.lww.com/joem/fulltext/2020/04000/labor_market_participation_before_and_after.11.aspx |
Flagship research goes deep inside the cell – with the aim of producing breakthroughs in individual cancer treatment by combining genetic data and other patient health data
The iCAN research team is producing new information and seeking solutions to… Read more Flagship research goes deep inside the cell – with the aim of producing breakthroughs in individual cancer treatment by combining genetic data and other patient health dataA team of researchers is bridging the gap between clinical research and registry studies with the aim of reinventing cancer drug research
Heidi Loponen, Senior Scientific Consultant at MedEngine Oy, uses register data in… Read more A team of researchers is bridging the gap between clinical research and registry studies with the aim of reinventing cancer drug researchResearchers analyse the patient and registry data of thousands of diabetics in order to improve their quality-of-life – around a third of type 1 diabetics suffer from kidney disease
The FinnDiane follow-up study, which has been ongoing for more than 20… Read more Researchers analyse the patient and registry data of thousands of diabetics in order to improve their quality-of-life – around a third of type 1 diabetics suffer from kidney diseaseResearch project examines young people’s access to psychiatric care: the open dialogue approach is bringing mental health work up to the present day
A research project is studying the open dialogue treatment model, in which… Read more Research project examines young people’s access to psychiatric care: the open dialogue approach is bringing mental health work up to the present day
What are my rights related to the processing of personal data?
As a data subject, you have the right to receive information about how we use your personal data. This information is available in the privacy notices on our Privacy Policy page.
In addition, you have the following rights when we process your personal data:
- Right of access to your personal data
- Right to rectify your data
- Right to restrict the processing of your data
- Right to object to the processing of your data
- Right to lodge a complaint with a supervisory authority
Read more by clicking on the sub-headings.
Right of access to your personal data (Article 15 of the GDPR)
You have as the data subject the right to obtain a copy of your personal data processed by Findata.
In addition, you have the right to be informed of:
- where your personal data was obtained
- why your personal data is needed
- for how long your personal data is needed
- whether your personal data have been disclosed and, if so, where.
- whether your personal data has been transferred outside the EU and what safeguards have been applied to it under the GDPR
- whether the processing is carried out using automation and
- how you can exercise your rights in relation to your personal data.
Right to rectify your data (Article 16 of the GDPR)
You have as a data subject the right to correct inaccurate data processed by Findata.
Right to restrict the processing of your data (Article 18 of the GDPR)
Data subjects have the right to restrict the processing of their data in certain circumstances. Processing may also be restricted as a result of other requests without the data subject’s explicit request.
You may request Findata to restrict the processing of your personal data in the following situations:
- if your data is incorrect
- if your data are processed unlawfully but you do not want them to be deleted
- if Findata no longer needs the data for the original purpose, but you need them for the establishment, exercise or defence of legal claims
- if you have objected to the processing of your data but the final decision is still under consideration
If we restrict the processing of your data, we will, where possible, inform all those to whom the data have previously been disclosed of the restriction.
Right to object to the processing of your data (Article 21 of the GDPR)
The data subject has the right to object to the processing of personal data by us at any time on grounds relating to their particular situation. In this case, we shall no longer process the data relating to this person, unless there are substantial and legitimate grounds for the processing which override the interests, rights and freedoms of the data subject, or for the establishment, exercise or defence of legal claims.
Right to lodge a complaint with a supervisory authority (Article 77 of the GDPR)
Under the GDPR, every data subject has the right to lodge a complaint with a supervisory authority if he or she considers that the processing of personal data concerning him or her infringes the GDPR. Complaints are addressed to the Office of the Data Protection Ombudsman.
Read more on the webpage of the Office of the Data Protection Ombudsman (tietosuoja.fi).
For more information about your rights under the GDPR and how to exercise them, visit the Data Protection Ombudsman’s website (tietosuoja.fi)
What data do my rights cover?
The right to access one’s data, correct one’s data, and restrict the processing of one’s data applies only to social and health data held by Findata at the time the request is made.
What data does Findata have?
Except for our ready-made datasets, we do not permanently store registry data. Instead, we serve as an intermediary between permit applicants (typically researchers) and data controllers, such as wellbeing services counties.
We retain personal data temporarily during the process of compiling, preprocessing, and verifying the data received from data controllers, before it is disclosed to the permit recipient. These data are stored for four months after they have been delivered to the permit holder.
Ready-made datasets
Ready-made datasets are precompiled and preprocessed datasets for which Findata permanently acts as the data controller.
What does the right to object mean?
You have the right to object to the use of your personal data for secondary purposes, such as scientific research. If you choose to exercise this right, Findata will no longer provide your data for secondary use from the date your request is processed.
Your objection will remain valid permanently unless you decide to withdraw it. Note that the objection does not apply to data that has already been disclosed before your request was submitted.
How is the right to object implemented at Findata?
When you object to the secondary use of your data through Findata:
- Your request is recorded in the case management system maintained by the Finnish Institute for Health and Welfare (THL).
- Your data will be removed from datasets received by Findata based on your personal identity code. Therefore, we must retain and process your personal identity code to implement the request.
Note: Submitting an objection request to Findata does not prevent other data controllers mentioned in the Secondary Use Act from providing your data for secondary use.
For example, hospitals hold data on a person’s treatment, and Social Insurance Institution of Finland (Kela) holds data on prescriptions issued to a person. Currently, there is no centralised system in Finland for objecting to the secondary use of data.
- Find information about data controllers and the content of registries on the page Data.
- See general instructions on objecting to the use of personal data: If you do not want your data processed (tietosuoja.fi)
Important considerations
- The Digital and Population Data Services Agency (DVV) does not process objections related to the disclosure of personal data for purposes defined in the Secondary Use Act.
- Restrictions on the disclosure of data in the Population Information System are governed by the Act on the Population Information System and the Digital and Population Data Services Agency’s Certification Services (§28).
- Read more (in Finnish): Tietojen luovuttamisen kieltäminen (dvv.fi)
- If you need access to your personal data, for example, to prepare, present, or defend a legal claim, you should submit the request directly to the original data controller.
Minors and data subject rights
Minors have the same rights as adults when processing personal data under the Secondary Use Act. The basic principle is that a minor who is able to form their own views is free to express their views on the use and processing of their personal data.
Can a child decide themselves whether to make requests?
In the case of minors, it is not possible to issue specific recommendations on the age at which a minor can independently decide on the use and processing of their data.
If taking into account their age and level of development the child is able to understand the matter and its significance, then they can decide on the exercise of their rights. Of course, this is not possible for very young children, but the older the child or young person is, the more decision-making power they have.
The guardian may make a request on behalf of the child
The guardian of an underage child may make, on the behalf of the child, a request that relates to the child’s rights as a data subject. It is recommended that the guardians discuss the request with the child and hear the child’s opinion on the matter before making the request, even if the child is not yet able to make a decision on the matter.
See step-by-step instructions on how to submit a request on Findata’s e-service
Inform the child
The guardians should inform the underage child of the request made on their behalf at the latest when the child is at an age and level of development where they can understand the matter. This is particularly important in situations where guardians have objected to the processing of personal data on behalf of a minor.
Objection requests are valid until further notice and thus continue to be valid even after the minor becomes an adult.
When is the exercise of rights not possible?
As a general rule, the rights of data subjects are not restricted and the data subject’s requests are complied with.
In some rare cases, researchers may be allowed to limit the rights of data subjects if the data is used for scientific or statistical studies. When this happens:
- The research project must prepare a separate impact assessment.
- This assessment must be submitted to the Office of the Data Protection Ombudsman before the project begins.
- We will evaluate whether the data can be disclosed despite the data subject’s objection.
- While the assessment is under review, we limit the processing of personal data.
Permit applicants may also restrict the right to object to data processing for educational purposes, but only if:
- The case is rare and the data is essential for the educational activity.
- The educator informs all participants about their legal duty of confidentiality and the consequences of violating it.
If a data subject objects to Findata processing their personal data, we will stop disclosing their data to permit holders. However, if the data was already disclosed before the objection, it cannot be deleted.
How do I exercise my rights?
You can exercise your rights related to the data processed by Findata through our e-service.
Findata must verify the identity of the person exercising their rights to ensure that actions are directed at the correct individual’s data. hat’s why our e-service uses Suomi.fi authentication.
Suomi.fi authentication is a secure login method used by Finnish public services. You can log in using:
- Online banking credentials
- A mobile certificate
- A smart card
Once your identity is verified, you can safely use our electronic services. For more details, visit suomi.fi.
How to exercise your rights in Findata’s e-service
- Go to asiointi.findata.fi.
- Click “Login”.
- Select Suomi.fi as the authentication method.
- If you are logged in using another method, log out first.
- Authenticate using online banking credentials, a mobile certificate, or a smart card.
- After authentication, click “Continue to service”.
- Select the appropriate form from the list by clicking the blue “Fill in the application” button.
- To object to the processing of personal data, select “GDPR –Request to object to the processing of personal data”.
- To request access to your personal data, select “GDPR – Request to access your personal data”.
- Fill in the form carefully.
- If you are submitting a request on behalf of a minor child or a person under guardianship, select “No” under “Is the personal identification number of the person who completed the application?” and complete the form accordingly.
- Finally, click the blue “Submit application” button.
- Depending on your device, the button may be on the right side or below the form.
If you want to exercise multiple rights or act on behalf of others, complete and submit all relevant forms separately for each person.
To receive notifications about your request:
- Click your name at the top of the e-service.
- Add your email address.
- Click “Save”.
Exercising your rights without using Findata’s e-service
If you cannot or do not wish to use Findata’s e-service, print out and use these forms:
You have the option to submit a request in person or by mail. See step-by-step instructions below.
Submitting a GDPR request in person
- Print and complete the request form.
- Visit the reception of the National Institute for Health and Welfare (THL) in Helsinki or Kuopio.
- Bring an identity document for verification.
- THL office addresses are available on THL’s website (thl.fi).
If you are submitting a request on behalf of a minor child or a person under guardianship, you must include a certificate of child custody obtained from the Population Information System. The request must align with the child’s presumed will and serve the child’s best interests. In cases of joint custody, the request must be made and signed by both guardians.
Submitting a GDPR request by mail
- Print and complete the request form.
- Notarisate the authenticity of your signature.
- Mail the request and address it to Findata.
- Consider sending the request as a register letter as it contains personal information.
- Findata’s postal address is P.O. Box 30, FI-00301 Helsinki, Finland.
If you are submitting a request on behalf of a minor child or a person under guardianship, you must include a certificate of child custody obtained from the Population Information System. The request must align with the child’s presumed will and serve the child’s best interests. In cases of joint custody, the request must be made and signed by both guardians.
How long does it take to process requests?
As a rule, we process requests within one month of receiving them. If the processing of the request is particularly complex for some reason, we may extend the processing time to a maximum of three months. We will send a reply on the implementation of the request or resolving the matter to the data subject as a Suomi.fi message.
Prohibiting contacting regarding registry research findings
The right to refuse contact based on Section 55 of the Secondary Use Act differs from other rights, as it does not apply to data processed by Findata.
You can submit a prohibition on contact regarding registry research findings electronically in the new version of OmaKanta or at any public healthcare service unit. This request cannot be made through Findata, Kela, or THL.
Prohibiting contacting regarding registry research findings on Omakanta
- Log in to OmaKanta at kanta.fi.
- Select ‘Siirry kokeilemaan OmaKannan uutta versiota’ on the homepage.
- In the sidebar, choose ‘Potilastietojen uudet luvat ja kiellot’
- Open the ‘Kiellot’ tab.
- Under ‘Yhteydenottokielto’, select ‘Rekisteritutkimuksen löydöksiä koskeva yhteydenottokielto’ and click ‘Muokkaa kieltoa’
- Select ‘Tee kielto’ to refuse contact.
Can I cancel an objection request?
If you’ve submitted a request to object to the processing of your personal data, you can cancel it at any time.
A minor can cancel a request made by their guardian, if they are considered mature enough to understand the matter based on their age and development.
How to cancel your objection request
You can cancel your objection in one of the following ways:
- Via the Suomi.fi service:
- Send a message to Findata through the Suomi.fi service.
- When sending the message, select “Terveyden ja hyvinvoinnin laitos” (Finnish Institute for Health and Welfare) as the recipient.
- In person:
- Visit the reception desk of the Finnish Institute for Health and Welfare in Helsinki or Kuopio.
- Bring an identity document for verification.
- THL office addresses are available on THL’s website (thl.fi).
Contact details
Data Protection Officer
tietosuojavastaava@findata.fi
